These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6110312)

  • 21. Perphenazine concentrations in human whole blood. A pilot study during anti-psychotic therapy using different administration forms.
    Hansen CE; Larsen NE
    Psychopharmacologia; 1974 Jun; 37(1):31-6. PubMed ID: 4415024
    [No Abstract]   [Full Text] [Related]  

  • 22. High-dosage and versatile drug therapy with treatment-resistant psychotic patients.
    Ketai R
    Hosp Community Psychiatry; 1976 Jan; 27(1):37-9. PubMed ID: 1338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response relationships of perphenazine in the treatment of acute psychoses.
    Hansen LB; Larsen NE; Gulmann N
    Psychopharmacology (Berl); 1982; 78(2):112-5. PubMed ID: 6817364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.
    Simpson JR; Thompson CR; Beckson M
    J Clin Psychopharmacol; 2006 Jun; 26(3):333-5. PubMed ID: 16702903
    [No Abstract]   [Full Text] [Related]  

  • 26. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients.
    Zarate CA; Tohen M
    Am J Psychiatry; 2004 Jan; 161(1):169-71. PubMed ID: 14702269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perphenazine serum levels in patients on standard doses.
    Haffner F
    Psychopharmacol Ser; 1989; 7():280-3. PubMed ID: 2687863
    [No Abstract]   [Full Text] [Related]  

  • 28. Oral intake of perphenazine decanoate.
    Larsen NE
    Ther Drug Monit; 1998 Dec; 20(6):724. PubMed ID: 9853996
    [No Abstract]   [Full Text] [Related]  

  • 29. [Recurrent gluteal injection abscesses as a complication of frequent intramuscular self-injection].
    Harsch IA; Pietzcker T; Wiest GH; Hahn EG; Ficker JH
    Med Klin (Munich); 2001 May; 96(5):298-9. PubMed ID: 11395996
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.
    Hansen LB; Larsen NE
    Psychopharmacology (Berl); 1977 Jul; 53(2):127-30. PubMed ID: 408838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depot perphenazine decanoate and enanthate for schizophrenia.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001717. PubMed ID: 10796445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation.
    Lindholm H; Ljungberg L
    Acta Psychiatr Scand Suppl; 1973; 246():52-6. PubMed ID: 4520279
    [No Abstract]   [Full Text] [Related]  

  • 33. The CATIE schizophrenia effectiveness trial.
    Delisi LE; Nasrallah HA
    Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
    [No Abstract]   [Full Text] [Related]  

  • 34. Determination of perphenazine and its sulphoxide metabolite in human plasma after therapeutic doses by gas chromatography.
    Larsen NE; Naestoft J
    J Chromatogr; 1975 Jun; 109(2):259-64. PubMed ID: 1150819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
    Remvig J; Larsen H; Rask P; Skausig OB; Skov S; Strömgren LS
    Pharmacopsychiatry; 1987 Jul; 20(4):147-54. PubMed ID: 3615572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.
    Altamura AC; Sassella F; Santini A; Montresor C; Fumagalli S; Mundo E
    Drugs; 2003; 63(5):493-512. PubMed ID: 12600227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Perphenazine enanthate. Results of a 1-year open multicenter study].
    Baruch P; Brion S; Broussolle P; Gayral LF; Ropert R; Volmat R; Porot M
    Encephale; 1989; 15(5):449-55. PubMed ID: 2686965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
    Knudsen P; Hansen LB; Højholdt K; Larsen NE
    Acta Psychiatr Scand Suppl; 1985; 322():41-50. PubMed ID: 3934921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose.
    Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE
    Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of linearity of kinetics for the neuroleptics perphenazine and zuclopenthixol.
    Linnet K
    Eur J Clin Pharmacol; 1997; 52(4):317-8. PubMed ID: 9248772
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.